Abstract：
Most patients with myasthenia gravis (MG) develop ocular manifestations during their illness and up to 22% may have isolated ocular myasthenia gravis (OMG). Apraclonidine elevates the eyelid by activating alpha-2 receptors on Muller\'s muscle, an accessory eyelid elevator muscle. In this study we evaluate the effect of apraclonidine in alleviating ptosis secondary to MG.
This clinical trial (NCT05045248) was done at the American University of Beirut Medical Center. Patients with ptosis secondary to MG were administered two drops of apraclonidine 0.5% solution to the most affected eye. We measured palpebral fissure height (PF), marginal reflex distance-1 (MRD1), marginal reflex distance-2 (MRD2), and levator function (LF) before drug administration and at 1, 5, 30, and 60 minutes after administration.
Ten participants were enrolled in the study. Improvement in all eyelid measurements was noted in all participants as early as 1 minute after apraclonidine administration. From baseline to 60 minutes after administration, average PF increased from 8.8 ± 1.9 mm to 14.2 ± 2.6 mm, MRD-1 from 1.7 ± 1.4 mm to 5.4 ± 2.9 mm, MRD-2 from 7.1 ± 1.3 mm to 8.8 ± 1.7 mm, and LF from 13.4 ± 2.9 mm to 17.5 ± 2.4 mm. All increases were statistically significant.
Apraclonidine may alleviate ptosis secondary to MG and may be an effective alternative treatment for this group of patients.
This clinical trial (NCT05045248) was done at the American University of Beirut Medical Center. Patients with ptosis secondary to MG were administered two drops of apraclonidine 0.5% solution to the most affected eye. We measured palpebral fissure height (PF), marginal reflex distance-1 (MRD1), marginal reflex distance-2 (MRD2), and levator function (LF) before drug administration and at 1, 5, 30, and 60 minutes after administration.
Ten participants were enrolled in the study. Improvement in all eyelid measurements was noted in all participants as early as 1 minute after apraclonidine administration. From baseline to 60 minutes after administration, average PF increased from 8.8 ± 1.9 mm to 14.2 ± 2.6 mm, MRD-1 from 1.7 ± 1.4 mm to 5.4 ± 2.9 mm, MRD-2 from 7.1 ± 1.3 mm to 8.8 ± 1.7 mm, and LF from 13.4 ± 2.9 mm to 17.5 ± 2.4 mm. All increases were statistically significant.
Apraclonidine may alleviate ptosis secondary to MG and may be an effective alternative treatment for this group of patients.
摘要：
目的：大多数重症肌无力（MG）患者在患病期间会出现眼部表现，高达22％的患者可能患有孤立的眼部重症肌无力（OMG）。阿普拉洛尼定通过激活穆勒肌肉上的α-2受体来提升眼睑，附属眼睑提升肌。在这项研究中，我们评估了apraclonidine在减轻MG继发下垂中的作用。
方法：本临床试验（NCT05045248）在贝鲁特美国大学医学中心进行。患有MG继发上睑下垂的患者向受影响最严重的眼睛服用两滴0.5％的阿克雷尼丁溶液。我们测量了睑裂高度（PF），边缘反射距离-1（MRD1），边缘反射距离-2（MRD2），给药前和给药后1、5、30和60分钟的提肌功能（LF）。
结果：10名参与者被纳入研究。所有参与者早在给药后1分钟就注意到所有眼睑测量的改善。从基线到给药后60分钟，平均PF从8.8±1.9mm增加到14.2±2.6mm，MRD-1从1.7±1.4mm到5.4±2.9mm，MRD-2从7.1±1.3mm到8.8±1.7mm，和LF从13.4±2.9毫米到17.5±2.4毫米。所有增加均具有统计学意义。
结论：阿普洛尼定可以缓解MG继发上睑下垂，可能是该组患者的有效替代治疗方法。
方法：本临床试验（NCT05045248）在贝鲁特美国大学医学中心进行。患有MG继发上睑下垂的患者向受影响最严重的眼睛服用两滴0.5％的阿克雷尼丁溶液。我们测量了睑裂高度（PF），边缘反射距离-1（MRD1），边缘反射距离-2（MRD2），给药前和给药后1、5、30和60分钟的提肌功能（LF）。
结果：10名参与者被纳入研究。所有参与者早在给药后1分钟就注意到所有眼睑测量的改善。从基线到给药后60分钟，平均PF从8.8±1.9mm增加到14.2±2.6mm，MRD-1从1.7±1.4mm到5.4±2.9mm，MRD-2从7.1±1.3mm到8.8±1.7mm，和LF从13.4±2.9毫米到17.5±2.4毫米。所有增加均具有统计学意义。
结论：阿普洛尼定可以缓解MG继发上睑下垂，可能是该组患者的有效替代治疗方法。
